The Corona (COVID-19) (SARS-CoV-2) cure using Blood Transfusion and Machine learning

ASIM. F. SAYYED

Abstract- ***(SARS-CoV-2; previously provisionally been named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the tip of 2019 had caused an outsized global outbreak and it is a significant public health issue. As of 6th May 2020, data from the World Health Organization (WHO) have shown that quite 3.4 Million cases out of which 1.27 M somehow manages to recover whereas 265k is unfortunately dead which is identified in 28 countries/regions. On 30th January 2020, WHO declared COVID-19 the sixth public health emergency of international concern? Its spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to possess a mean period of 6.4 days, and a basic reproduction number of two. Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the foremost common symptom, followed by a cough. Bilateral lung involvement with ground-glass opacity was the foremost common finding from CAT images of the chest. The one case of SARS-CoV-2 pneumonia within the USA is responding well to redeliver, which is now undergoing a test in China. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the first intervention getting used. However, public health authorities should keep monitoring true closely, because the more we are visiting to study this novel virus, and its associated outbreak. The purpose of this study is to put forth a theory about how blood transfusion from a corona recovered patient to a normal person could help the normal person to be immune to the virus. This treatment can also be termed as passive immunization as of PMC paper on blood transfusion in paragraph 1.***

I. INTRODUCTION

We can found the trace of Passive immunization (PI) in the Ebola infection episode in West Africa has turned the spotlight onto the conceivable utilization of improving entire blood and recuperating plasma in the treatment of irresistible illnesses since they are the main restorative system accessible now and again, given the inaccessibility of immunizations, drugs or other explicit medications. Improving blood items could be a legitimate choice in the treatment/prophylaxis of a few irresistible illnesses both were in the relationship with different medications/preventive measures as the main treatment when a treatment isn't accessible. The same case which we observe here is the case of a smallpox epidemic where there was no certain resource or vaccine was available for smallpox. The same kind of passive immunization could be used here and if we merge the science with engineering specifically machine learning we can get closer to build the vaccine much earlier

Passive immunization (PI) for the counteraction and treatment of human irresistible ailments and its related idea of misleadingly gained latent insusceptibility can be followed back to the twentieth century when explicit antibodies were looked for from serum of animated creatures (particularly bunnies and ponies). Human blood was additionally recognized as a wellspring of antibodies. PI is a procedure to accomplish prompt momentary vaccination against irresistible operators by managing pathogen-explicit antibodies. Since its presentation, it has demonstrated to be lifesaving for some intense contaminations and, likewise indicated potential applications in malignant growth therapy. Even though anti-microbials have generally superseded the utilization of PI in bacterial diseases, it stays a significant device in the treatment of numerous viral contaminations when immunizations or other explicit medications are not accessible.

II. PROPOSED SYSTEM

If we look back on Convalescent blood products (CBP), gotten by gathering entire blood or plasma

from a patient who has endured past contamination and created humoral insusceptibility against the pathogen answerable for the sickness, they are a potential wellspring of explicit antibodies of human origin. The transfusion of CBP can kill the pathogen and inevitably prompts its destruction from the blood flow. Distinctive CBP has been utilized to accomplish misleadingly obtained uninvolved immunity:

i) convalescent plasma (CP) or convalescent serum (CS);
ii) convalescent whole blood (CWB) pooled human immunoglobulin for intramuscular administration or intravenous ;
iii) polyclonal or monoclonal antibodies and
iv) high-titer human Ig

The plasma or blood sharing maybe this popular therapeutic tool for several reasons: larger volumes is also collected per session,

Now, these collected blood samples can be used as the dataset for the machine operations so that our machine can use various machine learning algorithms and can learn from this data because the number of people affected by the corona (COVID-19) is multiplying every second hence the prospect of more frequent donations is more which indicates that our machine is getting a frequent data by which it can train itself also known as reinforcement learning and possibly can develop a cure on its own. The recruitment of donors living in areas within which a scourge has broken out can give the added value of providing specific, artificially immunity against the local agent while CBP supplied from other regions could even be less effective. Nevertheless, the identification, selection, and recruitment of potential donors are also difficult, as convalescent subjects must also meet donor selection criteria, as because many factors are involved like whether the subject's body will accept the new information to fight this virus or not, whether the subject's body falls sick and be a possible home for the virus and anything of that sort. However, due to the potential importance of the treatment some donor selection criteria, is designed to safeguard the donor's health, maybe relaxed, as also suggested by the World Health Organization (WHO). Notably, the employment of pathogen inactivation could guarantee additional safety

Human bodies fight with the virus in the same way as that of a computer's antivirus fights with the virus Human bodies too generates log files like machines and these log files are further used to defeat the same types of the virus if at all they are encountered in future. As we already know a vaccine is nothing but a part of the virus which is given to the human body. Vaccines help create resistance by mirroring a disease. This sort of disease, notwithstanding, never causes ailment, however, it causes a safe framework to deliver T-lymphocytes and antibodies. Here and there, in the wake of getting an immunization, the impersonation contamination can cause minor side effects, for example, fever. Such minor side effects are ordinary and ought to not out of the ordinary as the body manufactures insusceptibility. When the impersonation contamination leaves, the body is left with a supply of "memory" T-lymphocytes, and B-lymphocytes that will recollect how to battle that disease later on. In any case, it regularly takes half a month for the body to deliver T-lymphocytes and B-lymphocytes after inoculation. In the human body T-lymphocytes and B-lymphocytes are the logs which store valuable information about how to defeat the virus.

The same is the situation with antivirus software whenever the antivirus software has coded the part of the virus is also coded so that the software can find the same structure and either quarantine the malicious software or completely remove it. But in both of the situation one thing is common they generate a memory or we can say a log file about how the virus has been eliminated

Passive immunization (PI) for the counteraction and treatment of human irresistible ailments can be a solution but this solution could have side effects too because multiple factors have to be taken into consideration. Some significant inquiries need answers, since giving entire plasma to an individual may even over-burden the framework since it may be a huge volume. There are no financially accessible tests in the market that could quantify the counteracting agent level in the plasma. Hence to learn the solution we can use machine learning here as we already have the data of recovered person as given by WHO (World Health Organisation).

We can see in the paper "Treatment of 5 Critically Ill Patients with COVID19 with Convalescent Plasma"
"The 5 benefactors of gaining strength plasma were between the ages of 18 and 60 years. The contributors had recuperated from SARS-CoV-2 disease and were welcome to give their healing plasma after composed educated assent was acquired. The total of what contributors had been recently determined to have research centre affirmed COVID-19 and therefore tried negative for SARS-CoV-2 and other respiratory infections, just as for hepatitis B infection, hepatitis C infection, HIV, and syphilis at the hour of blood gift. The contributors had been well (asymptomatic) for in any event 10 days, with a serum SARS-CoV-2–explicit ELISA counters acting agent titer higher than 1:1000 and a killing neutralizer titer more prominent than 40. Following the gift, 400 mL of gaining strength plasma was gotten from every giver by apheresis, and the plasma was promptly transfused to the beneficiaries around the same time it was acquired"

When the plasma treatment is applied to multiple bodies they start reacting in different ways some bodies have developed the coronavirus some have successfully accepted the plasma levels and recovered faster whereas the other bodies have taken a much longer time to recover this shows that everybody has its fighting as well as accepting plasma levels

This plasma level is closely related to the bloodstream as it is we have a lot of data on recovered patients thankfully more than dead people

We can use this data to generate multiple datasets if we just see at the bottom line we need 3 types of data sets

1) People recovered from COVID19 (blood reports)(possibly these changes will mostly be similar)
2) people died from COVID-19(blood reports)

3) What happened when the infected person is treated with blood plasma(what all chemical changes their bodies went through)(possibly these changes will mostly be similar (as already discussed earlier))

   3a) Data of the person before blood plasma treatment based on his/her blood group (plasma levels should be monitored)

   3b) Data of a person after blood plasma treatment based on his/her blood group (plasma dosage should be monitored)

   3c) How many days does an individual needs to completely recover from the virus after blood plasma treatment (based on their blood groups)

   3d) How many people have died with this procedure and what was the level of plasma in their bloodstream and how much was injected

Since we have a lot amount of data we can go for convolution neural network here

Here we are going to have multiple modules

- Module1

Which will show how critical the situation of the currently affected person is.

This can be done by using dataset number 2 when the new blood report of a new person will be entered our model and it will get compared with all the blood reports of other patients if the report has matched with certain percentage our model will display the percentage of his/her severity

- Module 2

This model will show how much less percentage of plasma is there in the patient's body and how much he/she can take in

The above report of module 1 will now be compared with dataset number 1. Which will compare the difference between both the blood samples based on their blood groups and the patients can be given immunity boosters based on his/her situation

- Module 3

In this module, we will use 3 data sets data set 3a, 3b and 3d by comparing all three datasets we can cancel out the exceeded plasma level because of which people are dead

By calculating the difference between the current plasma level and the plasma level inserted into the patients and the patents died because of this procedure we can find out the accurate level of plasma.

- Module 4

Here we will use 2 data sets 3b and 3c which will help us to know that how many days will it take his/her body to be immune to the virus and how much dosage should be given to the person.

In every module if we observe we will find that every human body treats viruses differently and has its way to fight with the virus .here we can see in the data set of one immune person will be slightly different from another immune person. As discussed earlier the way of fighting, are the individual strategies of the human body to fight with the virus which we have here in the form of a data set i.e 3c & 3d

Now we just need to split the 3c and 3d dataset based on blood group and we can get the amount of blood plasma that is needed to be given and how much time will the person take approximately to recover

III. HISTORY

Studies directed during the Spanish flu pandemic of 1918 to 1920 recommended that the utilization of CBP can be effective and just because CP was distinguished as a potential treatment for the spread of viral diseases. within the subsequent decades, possible therapeutic efficacy was claimed for the management of measles, Argentine viral infection, influenza, chickenpox, infections by cytomegalovirus, parvovirus B19, and, more recently, geographic area H1N1, respiratory syndrome coronavirus (MERS-CoV) and severe and H5N1 avian flu. acute respiratory infections (SARI) viruses. Furthermore, a meta-analysis on Spanish influenza-CBP (involving 8 suitable studies for a whole of 1,703 patients) showed a significantly reduced mortality risk within the treated patients and suggested that CBP could also be evaluated within the treatment of H5N1-related diseases Account investigations indicated "steady proof for a decrease in mortality", particularly with early CP organization. Be that as it may, as studies were "usually of low or very mediocrity, needed benchmark groups, and at moderate or high danger of inclination", the creators asserted that "this treatment ought to be concentrated inside the setting of an all-around planned clinical preliminary or other proper assessment", including the treatment of MERS-CoV infection35. To the extent concerns CBP inside the treatment of haemorrhagic fevers, in 1976 CP was utilized for a fille contaminated with EBOV inside the Democratic Republic of Congo. the young lady was dealt with, without benefits, with plasma from somebody who had to endure disease with the firmly related Marburg virus. Two units were transfused to a tainted research centre labourer and in this way, the subject's recuperation recommended the conceivable remedial impact of CP for EBOV patients. CP was likewise used to treat patients with an Argentine viral disease brought about by the Junín virus. during a twofold visually impaired preliminary dispensed in 1979, patients treated with CP had a lower demise rate contrasted with subjects treated with "ordinary plasma". An examination of 23 sequential yearly pestilences of Argentine viral disease during a very gathering of 4,433 patients, saw from 1959 to 1983, demonstrated a tremendous distinction in general mortality between patients made do with regular treatment or CP (42.85% versus 3.29%). Immunotherapy has additionally endeavoured through the inactive exchange of insusceptibility with CP from patients who had recuperated from Crimean Congo viral contamination, yet the adequacy of this treatment for this ailment remains not clear43. Since the first EBOV flare-up in Congo, aloof inoculation in contaminated creatures (for example monkeys) has been acquired with the organization of IgG arrangements from ponies hyper-inoculated with EBOV along these lines proposing a potential use in humans44–47. during a 1995 flare-up in Kikwit, Zaire, eight patients got 150–400 mL of CWB and seven made due, for a passing pace of 12.5% when contrasted with 80% in untreated patients48. Notwithstanding, give the deficient number of treated patients and accordingly the lack of control subjects, the creators perceived the high danger of their work not being a delegate and including frustrating issues. In 2007, Oswald and partners revealed a disappointment of aloof exchange to shield macaques against challenge with EBOV49. These negative discoveries stood out from the previously mentioned asserted breezes up inside the treatment of EBOV contamination and featured the need for better understanding not just of the qualities and titer of antibodies ready to influence the course of ailments. In 2012, Dye and colleagues revealed that latently moved species-coordinated polyclonal IgG had the option to give all-out insurance in Filovirus-tested non-human

primates still because the upkeep of adequately elevated levels of IgG after various organizations until the host's versatile invulnerable reactions could likewise be enlisted to clear the disease. inside the indistinguishable year, Olinger et al.51 and Qiu et al.52 revealed that killing the enemy of EBOV glycoprotein monoclonal antibodies ensured monkeys when the deadly infection challenge.

IV. FUTURE EXPERIENCE AND RECENT PERSPECTIVES

Right now, considering the nonappearance of authorized remedial and symptomatic instruments to confine the EBOV flare-ups in West African nations, the WHO has organized various items for additional examination through human testing. These incorporate two up-and-comer immunizations, a short rundown of antiviral medications, EBOV diagnostics, and CWB and CP. The assessment of the conceivable job of CP and CWB as helpful devices are being directed through controlled clinical examinations that, it is to be trusted, will give proof-based information to assess their security and efficacy. As indicated by the WHO's models, just clinically asymptomatic survivors, 28 days in the wake of being released and who has twice tried negative for EBOV RNA by sub-atomic strategies, ought to be considered as potential CBP donors. Besides, the release records of recuperated patients ought to be looked into before considering them as potential contributors in consistence with national giver determination rules. Be that as it may, given the life-sparing capability of CBP gave by overcomers of this deadly sickness, the WHO has proposed evaluating and conceivably loosening up the benefactor determination models utilized in the nation being referred to. Potential givers who meet the WHO standards of recuperation from EBOV ailment and who additionally meet the benefactor determination measures and have given educated assent should then be exposed to pre-gift testing to survey their last appropriateness for a gift, as per national strategy and routine techniques. The production of a register or database of patients recuperated from EBOV ailment as potential CBP contributors are firmly supported. An as of late distributed WHO rule gives further specialized data on the assortment and readiness of CBP, which ought to be performed via prepared staff working under standard working methodology as per global guidelines. The WHO likewise managed key contemplations empowering powerful data, instruction, and commitment of patients recuperated from EBOV infection and the networks in which they live, to consider gifts of CBP for use in the treatment of EBOV sickness and use in clinical preliminaries in the influenced countries. A WHO extra direction report additionally manages the morals of utilizing CBP during EBOV epidemics.

CWB gave by patients who have recuperated from an EBOV contamination has been directed in Sierra Leone in a preliminary run by the legislature since late 201459. A stage I/II pilot clinical preliminary of CP started in Liberia simultaneously and is right now selecting patients under the sponsorship of Clinical Research Management Inc. (a clinical research association) with the USA government and the Bill and Melinda Gates Foundation. The investigation, wherein it is proposed to treat EBOV-contaminated patients with 90–110 mL of CP from two ABO-good contributors, will assess the adequacy and wellbeing of CP and could give significant outcomes just as the responses to a few inquiries in regards to this still deficiently comprehended helpful tool.

Guinea is likewise at present running a plasma preliminary through an association with establishments in Belgium, the UK, France, and Médecins Sans Frontiers. Up until this point, around 100 patients have been transfused in Sierra Leone and Guinea. Albeit as of late, Gutfreund and Meyers recommended that CP-based treatment isn't just more secure yet besides more proficient than CWB treatment in lessening mortality, accessible information from the previously mentioned preliminaries are as of now despite everything being examined for complete proof of adequacy and guidelines are being created.

Moreover, toward the finish of December 2014, the European Blood Alliance propelled another convention, created and oversaw by the UK National Health Service Blood and Transplant (NHSBT), for the coordination of European loads of EBOV CP. Accessibility of CP from survivors in the European Union/European Economic Area is checked by the European Blood Alliance yet is at present rare and a treatment convention is under development64. The

German Federal Government has reacted to the Ebola episode with an inventory of different estimates, for example, an examination committed to the utilization of hyperimmune plasma attempted by the Paul-Ehrlich Institute (Langen, Germany).

As far as we could know, in any event, 24 instances of EBOV disease have been treated in Europe and the USA. A considerable lot of these cases were human services laborers who contracted EBOV in West Africa and were moved back to their nations of origin for treatment. The vast majority of them got CP in relationship with different other exploratory medications and progressed to strong consideration. For American patients, investigational new medication and empathetic use investigational gadget exception (for pathogen-diminished plasma) has been utilized as an instrument to allow assortment and clinical utilization of CP65.

The Cerus Corporation (Concord, CA, USA) has as of late presented a clinical convention to the USA Food and Drug Administration to permit the utilization of the INTERCEPT Blood System® for the treatment of CP gathered from EBOV ailment survivors as an extra security measure to lessen the danger of any transfusion-transmitted contamination through plasma utilized as an inactive safe treatment in patients with genuine or perilous EBOV disease. A similar innovation, for a similar explanation, is being utilized in African preliminaries. Truth be told, after assortment, each plasma unit from the above giver source ought to experience pathogen inactivation by an affirmed technique to upgrade the security edge of transfused units. In such manner, a recently evolved procedure of dissolvable/cleanser inactivation for use on single-giver plasma or smaller than expected pools of plasma in blood foundations in creating countries could likewise be misused as an extra security tool.

CONCLUSION

The ongoing coronavirus throughout the word has turned the spotlight onto the conceivable utilization of CBP in the treatment of irresistible sicknesses because, at times, because of the inaccessibility of immunizations, drugs, or other explicit medications, such blood items are the main helpful procedure accessible. Albeit numerous investigations have detailed the viability and security of CP implantation in the treatment of different contaminations (particularly those brought about by infections), because of the absence of enormous scope, randomized, all around structured clinical preliminaries, in general, consider CP an "experimental" treatment. Since a large portion of the investigations directed so far are case arrangement, they can just furnish us with low-quality logical proof that might be illustrative of the objective populaces. Besides, none of the investigations on restorative CBP utilization must appear to have thought about the likelihood that such treatment could be destructive. Dengue is a maybe not pertinent, yet calming, case of a disease for which resistant upgrade of pathogenicity is considered possible. This malady "gives the most plentiful model in human medication and the best human ailment trouble brought about by the wonder of inherent counteracting agent subordinate contamination upgrade" which, through the disease of monocytes or macrophages with irresistible invulnerable edifices, stifles inborn antiviral frameworks subsequently permitting logarithmic intracellular development of the virus. This instrument through which infections exploit against viral humoral safe reactions to taint have target cells isn't constrained to dengue.

Information that will be accessible sooner rather than later may likewise upgrade information on EBOV and the qualities and safe reaction of hosts. Data about the EBOV proteins focused by the resistant framework (particularly by T cells) during common diseases ought to help deliver viable vaccines and fast advancement in this field could utilize out of date, not invaluable CP. There might be major authoritative and mechanical difficulties in agreeing to standard working strategies for the collection, creation, and utilization of CBP in creating African nations. In such a manner, it is additionally worth referencing the moral and down to earth challenges of structuring randomized clinical preliminaries on the utilization of CBP, especially concerning the determination of control bunch patients. If we see the process throughout we will find that the human recovery system against virus works more or less same as that of computer viruses

And these data can be further be used to train a machine and expect genuine results from the automation.

In any case, considering the conceivable earnestness and the high death pace of EBOV disease, it is critical to give whatever number individuals as would be prudent an opportunity to get protected and viable items that could spare their lives. Aggregate endeavours ought to be centred not just around the complete assessment of the practicality of plasma treatment for irresistible maladies yet additionally on encouraging access to across the board and reasonable medicines, particularly in creating nations. To wrap things up, guarantee that the creation and utilization of CBP occur as indicated by exact moral and controlled conditions, and clinical preliminaries are finished to deliver the proof base for a potential job of these results of human cause in readiness plans for future episodes of rising or re-rising pathogens.

REFERENCES

[1] Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003; 16:69–86. [PubMed] [Google Scholar]

[2] Wang SF, Tseng SP, Yen CH, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014; 451:208–14. [PMC free article] [PubMed] [Google Scholar]

[3] Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr. 2014; 2 AID-0022-2014. [PubMed] [Google Scholar]

[4] Olsen CW, Corapi WV, Ngichabe CK, et al. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol. 1992; 66:956–65. [PMC free article] [PubMed] [Google Scholar]

[5] Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: a historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013; 158:1445–59. [PubMed] [Google Scholar]

[6] Ubol S, Halstead SB. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol. 2010; 17:1829–35. [PMC free article] [PubMed] [Google Scholar]

[7] Colebunders RL, Cannon RO. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis. 2015; 211:1208–10. [PubMed] [Google Scholar]

[8] Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. J Thromb Thrombolysis. 2015; 39:118–28. [PMC free article] [PubMed] [Google Scholar]

[9] Picker SM. Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus. 2013; 11:343–8. [PMC free article] [PubMed] [Google Scholar]

[10] The New York Times. How many Ebola patients have been treated outside of Africa? [Accessed on 21/05/2015]. Updated Jan. 26, 2015 Available at http://www.nytimes.com/interactive/2014/07/31/world/africa/ebola-virus-outbreak-qa.html?_r=0.

[11] European Blood Alliance. Newsletter 2015-1. [Accessed on 21/05/2015]. Available at: http://www.sweba.se/sites/default/files/EBA%20Newsletter%202015_1.pdf.

[12] European Centre for Disease Prevention and Control. Overview of Ebola research – March 2015 ECDC. Treatment and vaccine development. [Accessed on 21/05/2015]. Last updated 5 March 2015 Available at http://ecdc.europa.eu/en/healthtopics/ebola_marburg_fevers/Pages/treatment-vaccines.aspx.

[13] World Health Organization. Essential medicines and health products. [Accessed on 21/05/2015]. Available at: http://www.who.int/medicines/ebola-treatment/emp_ebola_therapies/en/

[14] World Health Organization. Community engagement and education, recruitment, and retention of people recovered from Ebola as potential donors for convalescent whole blood and

plasma. Interim guidance for National Health Authorities, Blood Transfusion Services, and researchers. Apr 2015. [Accessed on 21/05/2015]. Available at: http://www.who.int/bloodsafety/interim-guidance_CWB-CP.pdf.

[15] Gulland A. First Ebola treatment is approved by WHO. Br Med J. 2014; 349:5539. [PubMed] [Google Scholar]

[16] Cohen J. Ebola vaccine: little and late. Science. 2014; 345:1441–42. [PubMed] [Google Scholar]

[17] Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012; 4:138ra81. [PubMed] [Google Scholar]

[18] Olinger GG, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies protect rhesus macaques. Proc Natl Acad Sci USA. 2012; 109:18030–5. [PMC free article] [PubMed] [Google Scholar]

[19] Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. PNAS. 2012;13:5034–9. [PMC free article] [PubMed] [Google Scholar]

[20] Mapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179:S18–23. [PubMed] [Google Scholar]

[21] Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis. 1999;179:S218–23. [PubMed] [Google Scholar]

[22] Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl. 1996;11:135–40. [PubMed] [Google Scholar]

[23] Ruggiero HA, Pérez Izquierdo F, Milani HA, et al. [Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases]. Presse Med. 1986;15:2239–42. [In French.] [PubMed] [Google Scholar]

[24] Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antivir Res. 1994;23:23–31. [PubMed] [Google Scholar]

[25] Enria DA, Briggiler AM, Fernández NJ, et al. Importance of dose of neutralizing antibodies in the treatment of Argentine hemorrhagic fever with immune plasma. Lancet. 1984;2:255–6. [PubMed] [Google Scholar]

[26] World Health Organization. Experimental therapies: growing interest in the use of whole blood or plasma from recovered Ebola patients (convalescent therapies) Ebola situation assessment - 26 September 2014. [Accessed on 21/05/2015]. Available at: http://www.who.int/mediacentre/news/ebola/26-september-2014/en/

[27] Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. [PMC free article] [PubMed] [Google Scholar]

[28] Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg. 1985;79:380–4. [PubMed] [Google Scholar]

[29] Mozdzanowska K, Furchner M, Washko G, et al. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol. 1997;71:4347–55. [PMC free article] [PubMed] [Google Scholar]

[30] Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses. 2013;7(Suppl

3):52–9. [PMC free article] [PubMed] [Google Scholar]

[31] Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion. 2010;50:1384–98. [PubMed] [Google Scholar]

[32] Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006;12:489. [PubMed] [Google Scholar]

[33] Young MK, Nimmo GR, Cripps AW, Jones MA. Post-exposure passive immunization for preventing measles. Cochrane Database Syst Rev. 2014;4:CD010056. [PubMed] [Google Scholar]

[34] World Health Organization Mers-Cov Research Group. State of knowledge and data gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in humans. PLoS Curr. 2013;12:5. [PMC free article] [PubMed] [Google Scholar]

[35] Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol. 2001;8:859–63. [PMC free article] [PubMed] [Google Scholar]

[36] Lesne E, Brodin P, Saint-Girons F. Plasma therapy in influenza. Presse Med. 1919;27:181–2. [Google Scholar]

[37] Miller OO, McConnell WT. Report of influenza treated with serum from recovered cases. Ky Med J. 1919;17:218–9. [Google Scholar]

[38] Jacobaeus Treatment of influenza pneumonia with serum from convalescents. Svenska Lakartidnin. 1920;18:385–99. [Google Scholar]

[39] Francis FD, Hall MW, Gaines AR. Early use of convalescent serum in influenza. Mil Surg. 1920;47:177–9. [Google Scholar]

[40] Behring E, Kitasato S. Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei thieren. Deutsche medizinsche Wochenschrift. 1890;16:1113–4. [Google Scholar]Brock TD, editor. Milestones in Microbiology: 1556 to 1940. Washington: ASM Press; 1998. p. 138. [Google Scholar]

[41] Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus. 2016;14(2):152-157. doi:10.2450/2015.0131-15

[42] World Health Organization. Interim guidance for national health authorities and blood transfusion services. Geneva: World Health Organization; Sep 2014. [Accessed on 21/05/2015]. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Available at: http://apps.who.int/iris/bitstream/10665/135591/1/WHO_HIS_SDS_2014.8_eng.pdf?ua=1. [Google Scholar]

[43] Dodd RY. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol. 2012;159:135–42. [PMC free article] [PubMed] [Google Scholar]

[44] Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci. 2014;51:120–5. [PMC free article] [PubMed] [Google Scholar]

[45] Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13:602–14. [PMC free article] [PubMed] [Google Scholar]

[46] Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020;323(16):1561–1562. DOI:10.1001/jama.2020.4940.